[go: up one dir, main page]

IT201600116554A1 - Probiotic yeasts as novel vaccination vectors - Google Patents

Probiotic yeasts as novel vaccination vectors

Info

Publication number
IT201600116554A1
IT201600116554A1 IT102016000116554A IT201600116554A IT201600116554A1 IT 201600116554 A1 IT201600116554 A1 IT 201600116554A1 IT 102016000116554 A IT102016000116554 A IT 102016000116554A IT 201600116554 A IT201600116554 A IT 201600116554A IT 201600116554 A1 IT201600116554 A1 IT 201600116554A1
Authority
IT
Italy
Prior art keywords
vaccination vectors
novel vaccination
probiotic yeasts
probiotic
yeasts
Prior art date
Application number
IT102016000116554A
Other languages
Italian (it)
Inventor
Mateus Bruno Goncalo Douradinha
Original Assignee
Fond Ri Med
Univ Of Pittsburgh – Of The Commonwealth System Of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fond Ri Med, Univ Of Pittsburgh – Of The Commonwealth System Of Higher Education filed Critical Fond Ri Med
Priority to IT102016000116554A priority Critical patent/IT201600116554A1/en
Priority to PCT/EP2017/079557 priority patent/WO2018091637A1/en
Publication of IT201600116554A1 publication Critical patent/IT201600116554A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IT102016000116554A 2016-11-17 2016-11-17 Probiotic yeasts as novel vaccination vectors IT201600116554A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IT102016000116554A IT201600116554A1 (en) 2016-11-17 2016-11-17 Probiotic yeasts as novel vaccination vectors
PCT/EP2017/079557 WO2018091637A1 (en) 2016-11-17 2017-11-17 Probiotic yeasts as novel vaccination vectors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102016000116554A IT201600116554A1 (en) 2016-11-17 2016-11-17 Probiotic yeasts as novel vaccination vectors

Publications (1)

Publication Number Publication Date
IT201600116554A1 true IT201600116554A1 (en) 2018-05-17

Family

ID=58609729

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102016000116554A IT201600116554A1 (en) 2016-11-17 2016-11-17 Probiotic yeasts as novel vaccination vectors

Country Status (2)

Country Link
IT (1) IT201600116554A1 (en)
WO (1) WO2018091637A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3138174A1 (en) * 2019-05-21 2020-11-26 David James O'hagan Yeast-based oral vaccination

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0518443A1 (en) * 1984-10-31 1992-12-16 Chiron Corporation Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
WO2001092470A2 (en) * 2000-03-02 2001-12-06 Emory University Dna expression vectors and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2508957C (en) 2002-12-16 2015-11-17 Globeimmune, Inc. Yeast-based vaccines as immunotherapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0518443A1 (en) * 1984-10-31 1992-12-16 Chiron Corporation Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
WO2001092470A2 (en) * 2000-03-02 2001-12-06 Emory University Dna expression vectors and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
H ZHANG ET AL.: "Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans", VACCINE, vol. 39, no. 33, 13 August 2015 (2015-08-13), ELSEVIER, pages 5140 - 5147, XP029272457, ISSN: 0264-410X *
L H NAGY ET AL.: "Chronic HIV infection enhances the responsiveness of antigen presenting cells to commensal Lactobacillus", PLOS ONE, vol. 8, no. 8, E72789, August 2013 (2013-08-01), Public Library of Science, pages 1 - 12, XP002772797, ISSN: 1932-6203 *
V CHAMCHA ET AL.: "Oral immunization with a recombinant Lactococcus lactis - expressing HIV-1 antigen on group A streptococcus pilus induces strong mucosal immunity in the gut", THE JOURNAL OF IMMUNOLOGY, vol. 195, 19 October 2015 (2015-10-19), The American Association of Immunologists, pages 5025 - 5034, XP021116244, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
WO2018091637A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
IL261621A (en) Genome-edited vaccine activator cells
DK3218504T3 (en) THREE-SEGMENTED ARENAVIRA AS VACCINE VECTORS
DK3194567T3 (en) Probiotic Bifidobacterium adolescentis strains
MA42543A (en) CONCATEMERIC PEPTIDIC EPITOPE RNA
PL3294325T3 (en) STRENGTHENING THE PERFORMANCE OF CAR-ENGINED T-CELLS WITH NUCLEIC ACID VACCINATION
DK3981437T3 (en) NUCLEIC ACID VACCINES
HUE053101T2 (en) Improved T cell preparations
HUE050790T2 (en) Recombinant probiotic bacterium
DK3157559T3 (en) ANTI-AXL ANTIBODIES
HUE053760T2 (en) SUV39h1-deficient immune cells
CL2016002146A1 (en) Immunostimulatory plasmids
DK3228312T3 (en) IMMUNE REGULATOR
EP3560512A4 (en) HERPES-ZOSTER VACCINE COMPOSITION
LT3122378T (en) MUTANT STAFILOCOKO ANTIGENS
DK3201222T3 (en) Recombinant mutants
IL247535A0 (en) Poxviral oncolytic vectors
DK3198017T3 (en) VIRUS-BASED EXPRESSION VECTORS AND USES THEREOF
EP3257548C0 (en) FACIAL SOAKER
IT201600116554A1 (en) Probiotic yeasts as novel vaccination vectors
LT3188755T (en) VACCINE
TH1501004685A (en) Eyelash cosmetics
TH1501006124A (en) fermented soy milk
DK3197487T3 (en) VACCINATION OF IMMUNE COMPROMISED INDIVIDUALS
TH1601003238A (en) Swine vaccine
TH1601003632A (en) Lactobacillus salivarius for the treatment of mastitis